CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Cellectis S.A.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 20, 2026
$0.93−0.11 (-11.01%)
Close on Oct 19, 2026
- Market cap
- $93.15M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | During market hours | $5.23M | $-0.22 | $-0.19 |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 20, 2026 | During market hours | $10.40M | $-0.26 | $-0.24 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 4, 2025 | During market hours | $16.73M | $-0.24 | $-0.22 |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 2, 2023 | During market hours | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 3, 2023 | During market hours | $178.00K | $-0.19 | $-0.15 |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 6, 2023 | During market hours | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 4, 2022 | During market hours | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Mar 3, 2022 | During market hours | – | – | – |
Press releases
Announcements Cellectis filed with the SEC
Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company
EX-99.1 to Form 6-K
Cellectis Announces Participation in Upcoming Investor Conferences
EX-99.1 to Form 6-K
Cellectis Reports Financial Results for the Second Quarter 2026
EX-99.1 to Form 6-K
PART I – FINANCIAL INFORMATION
EX-99.1 to Form 6-K
Cellectis to Report Second Quarter Financial Results on August 6, 2026
EX-99.1 to Form 6-K
Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026
EX-99.1 to Form 6-K
Voting Results for the Combined General Meeting of Shareholders
EX-99.1 to Form 6-K
A corporation (“SA”) with a share capital of 5,029,549.70 euros
EX-99.1 to Form 6-K
Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026
EX-99.1 to Form 6-K
Cellectis Reports Financial Results for the First Quarter 2026
EX-99.1 to Form 6-K
PART I – FINANCIAL INFORMATION
EX-99.1 to Form 6-K
Cellectis to Report First Quarter Financial Results on May 11, 2026
EX-99.1 to Form 6-K
Cellectis Announces 2026 Strategy and Catalysts
EX-99.1 to Form 6-K
Cellectis Announces Arbitral Decision in Dispute with Servier
EX-99.1 to Form 6-K
PART I – FINANCIAL INFORMATION
EX-99.1 to Form 6-K
Cellectis to Present a Development Update for eti-cel at ASH 2025
EX-99.1 to Form 6-K
Cellectis to Report Third Quarter Financial Results on November 7, 2025
EX-99.1 to Form 6-K
Cellectis’ R&D Day Highlights Lasme-cel’s
EX-99.1 to Form 6-K
Cellectis Reports Second Quarter 2025 Financial Results & Business Updates
EX-99.1 to Form 6-K
PART I – FINANCIAL INFORMATION
EX-99.1 to Form 6-K
Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025
EX-99.1 to Form 6-K
Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025
EX-99.1 to Form 6-K
Shares represented by the votes cast
EX-99.1 to Form 6-K
Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025
EX-99.2 to Form 6-K
Cellectis’ Annual Shareholders General Meeting to be Held on June 26, 2025
EX-99.1 to Form 6-K
A corporation (“SA”) with a share capital of 5,014,561.35 euros
EX-99.1 to Form 6-K
PART I – FINANCIAL INFORMATION
EX-99.1 to Form 6-K